urotecin 5 mg filmsko obložene tablete
teva pharma b.v. - solifenacin - filmsko obložena tableta - solifenacin 3,8 mg / 1 tableta - solifenacin
urotecin 10 mg filmsko obložene tablete
teva pharma b.v. - solifenacin - filmsko obložena tableta - solifenacin 7,5 mg / 1 tableta - solifenacin
rastocin
injekcije
deca durabolin 50 mg/ml raztopina za injiciranje
raztopina za injiciranje - nandrolon
fulvestrant accord 250 mg raztopina za injiciranje v napolnjeni injekcijski brizgi
fulvestrant - raztopina za injiciranje v napolnjeni injekcijski brizgi - fulvestrant 250 mg / 1 brizga - fulvestrant
fulvestrant ever pharma 250 mg raztopina za injiciranje v napolnjeni injekcijski brizgi
fulvestrant - raztopina za injiciranje v napolnjeni injekcijski brizgi - fulvestrant 250 mg / 1 brizga - fulvestrant
deca durabolin 50 mg/ml raztopina za injiciranje
raztopina za injiciranje - nandrolon
mhyosphere pcv id
laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - prašiči - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.
ibandronska kislina arrow 150 mg tablete
arrow aps - ibandronska kislina - tableta - ibandronska kislina 150 mg / 1 tableta - ibandronska kislina
ibandronska kislina arrow 150 mg tablete
arrow aps - ibandronska kislina - tableta - ibandronska kislina 150 mg / 1 tableta - ibandronska kislina